Aura Biosciences, Inc. Proceeds from Common Stock Issued
Aura Biosciences, Inc. (AURA) reported Proceeds from Common Stock Issued of $259.38 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-08-11
- Aura Biosciences, Inc. proceeds from issuance of common stock for the quarter ending 2025-12-31 was $0.00.
- Aura Biosciences, Inc. proceeds from issuance of common stock for the quarter ending 2025-09-30 was $0.00.
- Aura Biosciences, Inc. proceeds from issuance of common stock for the quarter ending 2024-12-31 was $0.00.
- Aura Biosciences, Inc. proceeds from issuance of common stock for the quarter ending 2024-09-30 was $0.00.
- Aura Biosciences, Inc. proceeds from issuance of common stock for fiscal 2025 was $46.52M.
- Aura Biosciences, Inc. proceeds from issuance of common stock for fiscal 2024 was $0.00.
- Aura Biosciences, Inc. proceeds from issuance of common stock for fiscal 2022 was $86.65M, a 10.11% increase from fiscal 2021.
- Aura Biosciences, Inc. proceeds from issuance of common stock for fiscal 2021 was $78.70M.
| Period end | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|
| 2026-06-30 | $259.38M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $0.00 derived: sum of 2 quarters · filed 2026-03-30 | $46.52M 10-K · filed 2026-03-30 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $46.52M 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $46.52M 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $0.00 derived: sum of 2 quarters · filed 2026-03-30 | $0.00 10-K · filed 2026-03-30 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $0.00 10-Q · filed 2025-08-13 | |||
| 2022-12-31 | $86.65M 10-K · filed 2023-03-15 | |||
| 2021-12-31 | $78.70M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |